Chargement en cours...
Botulinum Toxin in Movement Disorders: An Update
Since its initial approval in 1989 by the US Food and Drug Administration for the treatment of blepharospasm and other facial spasms, botulinum toxin (BoNT) has evolved into a therapeutic modality for a variety of neurological and non-neurological disorders. With respect to neurologic movement disor...
Enregistré dans:
| Publié dans: | Toxins (Basel) |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7827923/ https://ncbi.nlm.nih.gov/pubmed/33430071 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/toxins13010042 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|